Torisel (temsirolimus) / Pfizer 
Welcome,         Profile    Billing    Logout  
 366 Diseases   40 Trials   40 Trials   1659 News 


«12...56789101112131415...2223»
  • ||||||||||  Torisel (temsirolimus) / Pfizer, Visudyne (verteporfin) / Novartis
    Journal:  Active epithelial Hippo signaling in idiopathic pulmonary fibrosis. (Pubmed Central) -  Oct 24, 2019   
    Activation of p-S6 was required for enhancing and stabilizing YAP, and the p-S6 inhibitor temsirolimus blocked nuclear YAP localization and suppressed expression of YAP target genes CTGF, AXL, and AJUBA (JUB). YAP and mTOR/p-S6 signaling pathways interact to induce cell proliferation and migration, and inhibit epithelial cell differentiation that may contribute to the pathogenesis of IPF.
  • ||||||||||  Novel therapy for relapsed childhood acute lymphoblastic leukemia () -  Oct 23, 2019 - Abstract #EHOC2019EHOC_7;    
    Since bcl-2 pathway prevents apoptosis, the efficacy of bcl-2 inhibitors, Navitoclax and Venetoclax, in ALL is being investigated...Palbociclib, CDK6 inhibitor, is used as monotherapy in KMT2A-r acute leukemia...Immunotherapy Antibody-based immunotherapy Blinatumomab: It is an antibody capable of binding to CD19 and CD3 and transmitting T-cell cytotoxicity to lymphoblasts presenting CD19...Denintuzumab mafodatin: It is a humanized CD19 antibody bound with monomethyl auristatin F (MMAF)...ADCT-402: It is a humanized anti-CD19 antibody conjugated with Pyrrolobenzodiazepine dimer cytotoxin...DT2219: It is a bispecific, recombinant, diphtheria toxin-based immunotoxin that recognizes CD19 and CD22-presenting cells...Inotuzumab ozogamicin: It is a novel monoclonal antibody against CD22 conjugated to the toxin Calicheamicin...Epratuzumab: It is a humanized monoclonal anti-CD22 antibody...Rituximab: It is a chimeric monoclonal CD20 antibody...Ofatumumab: It is a humanized anti-CD20 antibody...Obinutuzumab: It a type II humanized anti-CD20 monoclonal antibody...Etanercept (anti-TNF) and Tociluzumab (anti IL-6) can be used in the treatment of cytokine release syndrome. There are many marching studies on CAR-T cell therapy.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Roche, Biogen
    Review, Journal:  Primary central nervous system lymphoma: Novel precision therapies. (Pubmed Central) -  Oct 18, 2019   
    Gene expression profiling and next-generation sequencing have recently provided plethora of data shedding light on pathogenic mechanisms sustain PCNSL and identifying potential vulnerable mechanisms to be explored therapeutically. Here, we review established molecular drivers of PCNSL and targeted drugs that may change the current therapeutic paradigm.
  • ||||||||||  sirolimus / generics
    Journal:  Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression. (Pubmed Central) -  Oct 9, 2019   
    Targeted drugs used against ccRCC, such as sirolimus and temsirolimus, which could not be identified with the pre-aggregated tumour signatures could be recovered using individual sample analysis. Thus, drug repositioning can be personalized by taking into account the gene expression profile of the individual's tumour sample.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Review, Journal:  Chemotherapy in Pancreatic Cancer: A Systematic Review. (Pubmed Central) -  Oct 8, 2019   
    There is a need to develop further strategies besides chemotherapy to improve the outcomes in pancreatic cancer treatment. Future studies should consider surgical interventions, combination chemotherapy, and individualized second-line treatment based on the prior chemotherapy.
  • ||||||||||  Avastin (bevacizumab) / Roche, paclitaxel / Generic Mfg.
    Review, Journal:  PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. (Pubmed Central) -  Oct 8, 2019   
    In a recurrent disease setting, mTOR inhibitors may result in improved progression-free survival, but we found no clear benefit in overall survival or tumour response rate. We await the publication of at least five ongoing studies investigating the role of PI3K/AKT/mTOR inhibitors in advanced or recurrent endometrial cancer before any conclusions can be drawn on their use.
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Preclinical, Journal:  A mouse model of 22q11.2 deletions: Molecular and behavioral signatures of Parkinson's disease and schizophrenia. (Pubmed Central) -  Oct 2, 2019   
    In addition, both SZ-associated and PD-relevant deficits in the model were ameliorated by treatment with a rapamycin analog, CCI-779. We now posit the utility of 22q11.2 deletion mouse models in investigating the mechanisms of SZ- and PD-associated manifestations that could shed light on possible common pathways of these neuropsychiatric disorders.
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen
    Intraspinal recurrence of mantle cell lymphoma: systemic and intrathecal chemotherapy (A6) -  Sep 30, 2019 - Abstract #DGHO2019DGHO_1404;    
    Even in elderly disabled patients intrathecal combined with systemic chemotherapy seems to be a helpful alternative compared to high dose methotrexate, ablative regimens or total spinal axis irradiation. As spinal location of relapse is rare, only a few data could be found in literature, and registry data may be useful.
  • ||||||||||  Afinitor (everolimus) / Novartis, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Safety of Concurrent Hypofractionated Radiation Therapy and Systemic Therapy for Renal Cell Cancer (ASTRO Innovation Hub) -  Sep 24, 2019 - Abstract #ASTRO2019ASTRO_4335;    
    Our data suggest that the addition of H-RT to a targeted therapy regimen in extracraneal metastatic RCC does not pose an unreasonably elevated risk to patients except for axitinib where an increase in bone marrow suppression was found. However, this data must be interpreted cautiously in the background of small sample size (14 patients in the axitinib cohort).
  • ||||||||||  Unbiased Drug Discovery Approaches to Identify Novel Radiosensitizers from Cancer Therapy Evaluation Program (CTEP) Portfolio of Drugs in Pancreatic Cancer (Room W176) -  Sep 24, 2019 - Abstract #ASTRO2019ASTRO_3533;    
    The cell dispensing was automated to ensure uniform seeding of cell number and the drugs were added at six different concentrations ranging from 0.1nM to 10uM at three incubation time points (1h, 2h, 4h) before or after 2 Gy exposure with or without capecitabine (10 uM)...Selumetinib, dabrafenib, and veliparib showed radiosensitization in HPAC cells; alisertib, dasatinib, AZD8186, copanlisib, and VX-970 showed radiosensitization in Panc1 cells; and AMG 232, temsirolimus, and olaparib showed radiosensitization in both Panc1 and HPAC cells... High-throughput clonogenic assays coupled with validation by classical clonogenic assays may provide an unbiased in vitro approach to compare putative radiosensitizers head-to-head and allow rational advancement of select agents for additional evaluation for repurposing as radiosensitizers.
  • ||||||||||  Votrient (pazopanib) / Novartis, Torisel (temsirolimus) / Pfizer
    Trial completion:  Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) (clinicaltrials.gov) -  Sep 24, 2019   
    P2,  N=69, Completed, 
    High-throughput clonogenic assays coupled with validation by classical clonogenic assays may provide an unbiased in vitro approach to compare putative radiosensitizers head-to-head and allow rational advancement of select agents for additional evaluation for repurposing as radiosensitizers. Active, not recruiting --> Completed
  • ||||||||||  Afinitor (everolimus) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Advanced renal cell carcinoma: First results from the prospective research platform CARAT for patients with mRCC in Germany (Poster Area (Hall 4)) -  Sep 11, 2019 - Abstract #ESMO2019ESMO_2998;    
    CARAT complements results of RCTs with prospective data on clinical and PROs for pts with mRCC in routine care. CARAT will show changes in the choice of treatment due to new approvals, applied sequences and investigate the effectiveness in a “real world” setting.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Erectile dysfunction in patients with metastatic renal cell carcinoma (Poster Area (Hall 4)) -  Sep 11, 2019 - Abstract #ESMO2019ESMO_1832;    
    Significant decrease in erectile function should be considered as a potential adverse event in male patients undergoing treatment of mRCC with targeted agents. Legal entity responsible for the study: The authors.
  • ||||||||||  Journal:  Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma (Pubmed Central) -  Sep 6, 2019   
    The use of both the combination Nivolumab + Ipilimumab and Cabozantinib is limited to intermediate and high-risk patients...Temsirolimus is only approved for high-risk patients...Furthermore, the combination of Lenvatinib + Everolimus and Axitinib are approved treatment options in second-line and further settings...As in previous years, the experts intended to provide recommendations for clinical practice. The results are presented here.
  • ||||||||||  sirolimus / generics
    Biomarker, Clinical, Journal:  Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas. (Pubmed Central) -  Aug 16, 2019   
    Moreover, no association between PIK3CA mutation and sensitivity to PI3K/AKT/mTOR inhibitors was observed in cervical carcinoma cells. These results suggest that in Japanese patients with cervical cancer, PIK3CA mutation and amplification cannot act as biomarkers for individualized molecular targeted therapy.
  • ||||||||||  Biomarker, Journal, PD(L)-1 Biomarker, IO Biomarker:  Overview of current and future systemic therapy for metastatic renal cell carcinoma. (Pubmed Central) -  Aug 10, 2019   
    In this review, current evidence related to the clinical use of targeted therapies and checkpoint inhibitors for the treatment of patients with mRCC is discussed. In addition, we review ongoing trials investigating combinations of checkpoint inhibitors with targeted agents and the identification of biomarkers to guide patient selection and enable individualization of therapy.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Review, Journal:  The role of mTOR pathway as target for treatment in adrenocortical cancer. (Pubmed Central) -  Aug 10, 2019   
    This review summarizes the results of the studies evaluating the expression of the mTOR pathway components in ACCs, the effects of the mTOR inhibitors alone or in combination with other drugs in preclinical models of ACC and the early experience with the use of these compounds in the clinical setting. The mTOR pathway seems a potential target for treatment of patients with ACC, but further investigation is still required to define the potential role of mTOR inhibitors alone or in combination with other drugs in the treatment of ACC patients.
  • ||||||||||  Journal:  Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma (Pubmed Central) -  Jul 28, 2019   
    ...These improvements are also reflected in recent discussions about 3 and more lines of therapy.Sunitinib, pazopanib, the combination of bevacizumab and interferon alpha, and temsirolimus are approved for first-line therapy of mRCC...Everolimus (after tyrosine kinase inhibitor (TKI) treatment), sorafenib (after cytokines) and axitinib (after treatment with sunitinib or cytokines) are other compounds available for second-line therapy.3 new substances have recently been approved for second-line therapy: Nivolumab, cabozantinib, and lenvatinib combined with everolimus can be used after VEGF-targeted treatment has failed...Study results from a phase III trial suggest that the sequences sorafenib-sunitinib and sunitinib-sorafenib are equally effective.The purpose of an interdisciplinary expert meeting on RCC was to work out joint treatment recommendations based on current data and clinical experience and to integrate them into clinical routine practice. The results are presented in this publication.
  • ||||||||||  Revlimid (lenalidomide) / Celgene, Torisel (temsirolimus) / Pfizer, Imbruvica (ibrutinib) / AbbVie, J&J
    Journal:  Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! (Pubmed Central) -  Jul 19, 2019   
    Similarly, lenalidomide and temsirolimus achieve only short term remissions. Novel approaches like CAR T-cells may have the potential to finally improve the so far dismal long term outcome of these patients.
  • ||||||||||  Recentin (cediranib) / AstraZeneca, Torisel (temsirolimus) / Pfizer
    Trial completion date, Metastases:  AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies (clinicaltrials.gov) -  Jul 8, 2019   
    P1,  N=50, Active, not recruiting, 
    Novel approaches like CAR T-cells may have the potential to finally improve the so far dismal long term outcome of these patients. Trial completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Biomarker, Trial completion date, Trial primary completion date:  FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib (clinicaltrials.gov) -  Jul 5, 2019   
    P1,  N=5, Active, not recruiting, 
    Trial completion date: Dec 2018 --> Dec 2019 Trial completion date: Jun 2020 --> Jun 2023 | Trial primary completion date: Jun 2019 --> Jun 2022